Responses

Download PDFPDF

Current treatments in diabetic macular oedema: systematic review and meta-analysis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Efficacy of the intravitreal anti-vascular endothelial growth factor (VEGF) agent ranibizumab on driving
    • Ediriweera Desapriya, Research Associate
    • Other Contributors:
      • Dr. Vahid Mehrnoush, Dr. Michael Fernando

    Diabetic macular edema (DME) is a common complication of diabetic retinopathy (1). Vision loss in patients with diabetes is often associated with diabetic macular edema, DME. Even though DME is a chronic condition, appropriate use of available effective treatment modalities of therapy can be used to prevent moderate and severe vision loss from DME (1).

    "Despite the current wider spectrum of treatments for Diabetic...

    Show More
    Conflict of Interest:
    None declared.